The 6 Best-Performing ETFs Over the Past Month

Joel Anderson |

So November is behind us and retail season is upon us. And while Movember may mean one thing to many people, certain ETFs treated it like the “mo” is short for “momentum.” As the year starts to wind down and major holidays start stacking on top of one another, it’s easy to start putting off any serious thought about your portfolio until the new year. However, the markets wait for no man (or woman). As such, here’s the six top-performing, non-leveraged ETFs of the last month:

1. SPDR S&P Pharmaceuticals ($XPH)

Index: S&P Pharmaceuticals Select Industry Index

Expense Ratio: 0.35 percent

Performance over last month: 11.85 percent

November proved a solid month for the nation’s biggest pharma companies. What’s more, it was a strong month for the health care industry as this is one of four ETFs in the sector to make the list.

2. iShares MSCI India Small-Cap Index Fund (SMIN)

Index: MSCI India Small-Cap Index

Expense Ratio: 0.74 percent

Performance over last month: 11.01 percent

This isn’t strictly a November gain as this includes an over 4 percent pop on Monday. But despite continuing concerns about the timing of the Fed’s taper, investors appear to be in a risk-on mode and willing to invest in volatile plays like emerging market small-cap companies.

3. SPDR S&P Biotech ETF ($XBI)

Index: S&P Biotechnology Select Industry Index

Expense Ratio: 0.35 percent

Performance over last month: 9.41 percent

With the second SPDR S&P health care ETF on this list, it’s clear that it was a good November not just for the sector, but for its biggest players.

4. PowerShares Dynamic Pharmaceuticals ($PJP)

Index: Dynamic Pharmaceuticals Intellidex Index

Expense Ratio: 0.60 percent

Performance over last month: 9.27 percent

The Pharmaceuticals Intellidex Index is comprised of 30 pharma companies and is designed to provide capital appreciation through evaluating companies based on investment merit critera that include price momentum, earnings momentum, quality, management action, and value.

5. iShares Nasdaq Biotechnology Index ETF ($IBB)

Index: Nasdaq Biotechnology Index

Expense Ratio: 0.48 percent

Performance over last month: 8.91 percent

Our final entry for the health care sector would seem to indicate that drug makers and biotech companies of all sizes were having a strong month in November.

6. iShares Dow Jones U.S Broker-Dealers ETF ($IAI)

Index: Dow Jones U.S. Select Investment Services Index

Expense Ratio: 0.48 percent

Performance over last month: 8.91 percent

Booming equities appear to have benefitted people selling equities in the process as this broker-dealer ETF gained almost 9 percent in November.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
BIOGY BioGaia AB (Sweden) ADR 11.44 0.00 0.00 0


Emerging Growth

Enertopia Corp

Enertopia Corp is engaged in the exploration of lithium in Nevada, USA. The Company's project includes Central Nevada Lithium Brine Projects.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…